osimertinib.
chemical compound, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, used as a medication to treat non-small-cell lung carcinomas with a specific mutation
AstraZeneca Ends Phase III Lung Cancer Trial
AstraZeneca reports a setback as its Phase III trial of volrustomig plus chemotherapy in PD-L1 negative metastatic non-small cell lung cancer is halted after an independent data review found it unlikely to meet primary endpoints, while another late-stage study in cervical cancer and other indications continues. In a positive contrast, AZN and partners SAFFRON showed that Tagrisso combined with Orpathys significantly improved progression-free and overall survival, underscoring a mixed near-term outlook but ongoing strength in its immuno-oncology pipeline.
Health · 8 sources · Aug 17, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About osimertinib
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Everything about osimertinib →